Robert Driscoll
Stock Analyst at Wedbush
(3.94)
# 1,750
Out of 4,407 analysts
343
Total ratings
39.4%
Success rate
6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterated: Buy | $58 | $28.98 | +100.14% | 25 | Jun 12, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $37 | $13.70 | +170.07% | 18 | Jun 11, 2026 | |
| CTMX CytomX Therapeutics | Reiterated: Buy | $11 | $3.01 | +265.45% | 18 | Jun 4, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $36 | $9.05 | +297.79% | 28 | Jun 4, 2026 | |
| CBIO Crescent Biopharma | Maintained: Buy | $27 | $17.92 | +50.67% | 5 | Jun 1, 2026 | |
| REPL Replimune Group | Rated: Hold | $18 → $6 | $8.88 | -32.43% | 17 | Jun 1, 2026 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | $14 | $1.75 | +700.00% | 14 | Jun 1, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $165 | $153.87 | +7.23% | 23 | Jun 1, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $38 → $30 | $8.19 | +266.30% | 6 | May 27, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $6 | $1.76 | +240.91% | 2 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $59.56 | +34.32% | 4 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $34 | $14.76 | +130.35% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $0.6861 | +774.51% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $33 | $30.94 | +6.66% | 11 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $26.99 | +96.37% | 14 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $7.58 | +45.12% | 26 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $7 → $5 | $8.75 | -42.86% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $4.18 | +139.23% | 14 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $76 → $36 | $13.56 | +165.49% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $18.24 | +102.91% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 | $23.80 | +72.27% | 23 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 → $25 | $8.05 | +210.56% | 9 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 → $1 | $0.381 | +162.47% | 4 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.75 | +6.67% | 13 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $5.93 | +355.31% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $1.15 | n/a | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.03 | n/a | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $125.59 | n/a | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $4.26 | n/a | 8 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $11.93 | n/a | 4 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $7 → $10 | $0.0001 | n/a | 2 | Mar 19, 2020 |
IDEAYA Biosciences
Jun 12, 2026
Reiterated: Buy
Price Target: $58
Current: $28.98
Upside: +100.14%
Cullinan Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: $37
Current: $13.70
Upside: +170.07%
CytomX Therapeutics
Jun 4, 2026
Reiterated: Buy
Price Target: $11
Current: $3.01
Upside: +265.45%
Kura Oncology
Jun 4, 2026
Reiterated: Buy
Price Target: $36
Current: $9.05
Upside: +297.79%
Crescent Biopharma
Jun 1, 2026
Maintained: Buy
Price Target: $27
Current: $17.92
Upside: +50.67%
Replimune Group
Jun 1, 2026
Rated: Hold
Price Target: $18 → $6
Current: $8.88
Upside: -32.43%
Black Diamond Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $14
Current: $1.75
Upside: +700.00%
Revolution Medicines
Jun 1, 2026
Reiterated: Buy
Price Target: $165
Current: $153.87
Upside: +7.23%
Corbus Pharmaceuticals Holdings
May 27, 2026
Reiterated: Buy
Price Target: $38 → $30
Current: $8.19
Upside: +266.30%
Pyxis Oncology
May 18, 2026
Reiterated: Buy
Price Target: $6
Current: $1.76
Upside: +240.91%
May 18, 2026
Reiterated: Buy
Price Target: $80
Current: $59.56
Upside: +34.32%
May 14, 2026
Reiterated: Buy
Price Target: $29 → $34
Current: $14.76
Upside: +130.35%
May 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $0.6861
Upside: +774.51%
May 14, 2026
Reiterated: Buy
Price Target: $19 → $33
Current: $30.94
Upside: +6.66%
May 14, 2026
Reiterated: Buy
Price Target: $53
Current: $26.99
Upside: +96.37%
May 13, 2026
Maintained: Hold
Price Target: $11
Current: $7.58
Upside: +45.12%
May 12, 2026
Maintained: Sell
Price Target: $7 → $5
Current: $8.75
Upside: -42.86%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $4.18
Upside: +139.23%
May 8, 2026
Reiterated: Buy
Price Target: $76 → $36
Current: $13.56
Upside: +165.49%
May 8, 2026
Maintained: Buy
Price Target: $37
Current: $18.24
Upside: +102.91%
Apr 22, 2026
Reiterated: Buy
Price Target: $41
Current: $23.80
Upside: +72.27%
Mar 13, 2026
Reiterated: Buy
Price Target: $80 → $25
Current: $8.05
Upside: +210.56%
Dec 19, 2025
Downgraded: Hold
Price Target: $6 → $1
Current: $0.381
Upside: +162.47%
Aug 7, 2025
Maintained: Hold
Price Target: $4
Current: $3.75
Upside: +6.67%
Jul 14, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $5.93
Upside: +355.31%
May 8, 2025
Maintained: Buy
Price Target: $7 → $6
Current: $1.15
Upside: n/a
Aug 14, 2024
Reiterated: Buy
Price Target: $8
Current: $2.03
Upside: n/a
Nov 19, 2021
Maintained: Buy
Price Target: $67
Current: $125.59
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $7 → $6
Current: $4.26
Upside: n/a
Oct 5, 2020
Maintained: Buy
Price Target: $8
Current: $11.93
Upside: n/a
Mar 19, 2020
Downgraded: Hold
Price Target: $7 → $10
Current: $0.0001
Upside: n/a